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ABSTRACT
Modulation of the intestinal microbial ecosystem (IME) is a useful target to establish probiotic efficacy in a healthy population.
We conducted a randomized, double-blind, crossover, and placebo-controlled intervention study to determine the impact of
Bifidobacterium bifidum strain Bb on the IME of adult healthy volunteers of both sexes. High-throughput 16S rRNA gene se-
quencing was used to characterize the fecal microbiota before and after 4 weeks of daily probiotic cell consumption. The intake
of approximately one billion live B. bifidum cells affected the relative abundance of dominant taxa in the fecal microbiota and
modulated fecal butyrate levels. Specifically, Prevotellaceae (P 0.041) and Prevotella (P 0.034) were significantly decreased,
whereas Ruminococcaceae (P 0.039) and Rikenellaceae (P 0.010) were significantly increased. We also observed that the pro-
biotic interventionmodulated the fecal concentrations of butyrate in a manner dependent on the initial levels of short-chain
fatty acids (SCFAs). In conclusion, our study demonstrates that a single daily administration of Bifidobacterium bifidum strain
Bb can significantly modify the IME in healthy (not diseased) adults. These findings demonstrate the need to reassess the notion
that probiotics do not influence the complex and stable IME of a healthy individual.
IMPORTANCE
Foods and supplements claimed to contain health-promoting probiotic microorganisms are everywhere these days andmainly
intended for consumption by healthy people. However, it is still debated what actual effects probiotic products may have on the
healthy population. In this study, we report the results of an intervention trial aimed at assessing the modifications induced in
the intestinal microbial ecosystem of healthy adults from the consumption of a probiotic product. Our results demonstrate that
the introduction of a probiotic product in the dietary habits of healthy people may significantly modify dominant taxa of the
intestinal microbiota, resulting in the modulation of short-chain fatty acid concentrations in the gut. The overall changes wit-
nessed in the probiotic intervention indicate a mechanism of microbiota modulation that could have potential effects on human
health.
The prevailing notion that the deliberate intake of viable cells ofcertain microorganisms through food and supplements may
be beneficial for health underlies the worldwide commercial suc-
cess of probiotic products. Probiotics have been defined as “live
microorganisms that, when administered in adequate amounts,
confer a health benefit on the host” (1). Therefore, a positive con-
sequence on consumer health is an intrinsic feature of any formu-
lation that is considered a probiotic. Accordingly, the European
Union considers the term probiotic a health claim per se (“refer-
ence to probiotic/prebiotic implies a health benefit” [2]). How-
ever, although numerous studies have demonstrated the efficacy
of different probiotic preparations in a number of pathological
conditions (3), the potential benefits associated with probiotic
consumption by the general (healthy) population remain unclear
(4). The lack of a clear cause-and-effect relationship between pro-
biotic intake and health benefits for the general consumer is the
most frequent reason stated by the European Food Safety Author-
ity (EFSA) for the rejection of all health claims requested for pro-
biotics.
The intestinal microbiota has been proposed as an additional
organ of the human body that performs numerous functions,
ranging fromvitamin production and immunomodulation to im-
provement of nutrient bioavailability and competitive exclusion
against potential detrimental microorganisms (5). Therefore,
modification of the intestinalmicrobial ecosystem (IME)may po-
tentially induce functional changes that affect host physiology (5)
and is generally recognized by certain health agencies (e.g., Italian
Ministry ofHealth andHealthCanada FederalDepartment) as the
primary element supporting probiotic efficacy. Studies that de-
scribe and demonstrate the ability of specific probiotics to impact
the IME of healthy consumers, however, remain limited (6, 7).
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Contradictory results have also been obtained (8), possibly owing
to differences in the microbial strain used, the number of viable
cells administered, and the product formulation. Furthermore,
the deep complexity and profound variability of microbiota com-
position among subjects can hinder the recognition of actual
modifications. As a consequence, the impact of a probiotic, di-
etary, or pharmacologic intervention on the IME can be studied
only by adopting sensitive analytical tools, such as 16S rRNA gene
profiling, and an appropriate trial design.
We therefore performed an intervention trial with a crossover
design and used 16S rRNA gene profiling together with short-
chain fatty acid (SCFA) quantification in fecal samples from
healthy adults to investigate the impact on the IME of a product
containing a single Bifidobacterium bifidum strain. The strain was
selected as a representative of a species that has been reported to
possess numerous host interaction properties (9), including
marked adhesion to enterocytes (10–12), immunomodulation
(12–14), and metabolism of mucin and human milk oligosaccha-
rides (15, 16).
MATERIALS AND METHODS
Participants. Thirty-eight healthy human volunteers (21 women and 17
men; age, 24 to 54 years; mean, 31 years) participated in the study, named
PROBIOTA-Bb: “Effect of the probiotic strainBifidobacteriumbifidumBb
on the fecal microbiota of healthy adults.” All patients provided written
informed consent, and the study protocol was approved by the Ethics
Committee for Research of the Università degli Studi di Milano (opinion
37/12, 19 December 2012). The procedures were carried out in accor-
dance with the approved trial synopsis. The following inclusion criteria
were adopted for the enrollment of participants: age between 18 and 55
years, good general health, and a signed consent form. The following
exclusion criteria were adopted: antibiotic therapy during the 1 month
prior to the first visit, intentional intake of probiotic or prebiotic products
1 month before the first visit, viral or bacterial enteritis during the 2
months before the first visit, presence of gastrointestinal disorders (e.g.,
diarrhea, inflammatory bowel disease, or irritable bowel syndrome), preg-
nancy or breastfeeding, and recent or presumed episodes of alcoholism or
drug addiction. Participants in the study were prohibited from eating
probiotic foods and supplements and any foods or supplements enriched
in prebiotic compounds. Traditional yogurt was allowed.
Experimental design. The PROBIOTA-Bb study was a randomized,
double-blind, and placebo-controlled crossover trial with two parallel
groups (Fig. 1). The study consisted of a 4-week prerecruitment (run-in)
phase, followed by random assignment of participants to group A (n 
16) or group B (n 19). The group A protocol included a 4-week probi-
otic treatment (one capsule every day for 4 weeks in addition to habitual
diet), followed by a 4-week washout period and a 4-week placebo phase.
GroupB followed the opposite sequence, with placebo, washout, and then
probiotic treatment. Participants received written and oral instructions to
store the capsules at room temperature, to avoid exposure of the capsules
to heat sources, and to consume one capsule every day in the morning at
least 15 min before breakfast with natural (not sparkling) water (alterna-
tively, to consume the capsule in the evening at least 3 h after the last meal
of the day).No research has testedwhichmode of administration is better,
ingesting probiotics on an empty stomach or withmeals. In this study, we
decided to invite volunteers to consume capsules on an empty stomach
because food intake may vary enormously from meal to meal and from
subject to subject, differently affecting cell transit through the stomach
and therefore diversely influencing probiotic activity.
The study consisted of five visits: before the run-in period (visit V0),
before and after the first treatment (V1 and V2, respectively), and before
and after the second treatment (V3 and V4, respectively) (Fig. 1). During
each consultation, participants completed a short food frequency ques-
tionnaire that was specifically prepared to include a section for items
considered potential sources of prebiotic fibers. In addition, participants
compiled a weekly Bristol stool chart to report their bowel habits.
Products used in the trial. The probiotic preparation consisted of
gelatin uncoated capsules filled with Bifidobacterium bifidum Bb isolated
from the stool from a healthy adult woman and available in the culture
collection of the section of Food Microbiology and Bioprocesses at the
Department of Food, Environmental and Nutritional Sciences (Univer-
sity of Milan). Viable and total bacterial cell counts were performed ap-
proximately 1 week before the beginning of the trial on several randomly
selected capsules. Viable counts were performed by serial dilutions and
plating on deMan-Rogosa-Sharpe (MRS) agar plates with the addition of
0.05% cysteine-HCl. After 72 h of anaerobic incubation at 37°C, we cal-
culated that each capsule contained 1.3  109  0.1  109 CFU. Total
bacterial cell counts, which were performed by cytofluorimetry (BD Ac-
curi C6; Becton Dickinson Italia, Milan, Italy) upon SYBR green cell la-
beling, revealed that each capsule contained 3.8  109 bacterial cells per
capsule. The capsules also containedmaltodextrin, cellulose powder, dex-
trose, a separating agent (magnesium salts of edible fatty acid), and silica.
Placebo capsules were identical and were filled with maltodextrin instead
of dry powder probiotic bacteria. This trial was registered at www.isrctn
.com/search?qISRCTN56945491 under trial no. ISRCTN56945491.
FIG 1 Schematic of the study design and flow.
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Collection of fecal samples and extraction of metagenomic DNA. A
fecal sample was collected from each participant in a sterile plastic pot no
more than 24 h before visits V1, V2, V3, and V4. According to the recom-
mendations for “storage conditions of intestinal microbiota matter in
metagenomic analysis” (17), participants were asked to preserve the sam-
ple at room temperature until delivery to the laboratory. At delivery, stool
specimens were immediately stored at 80°C until metagenomic DNA
extraction, which was performed within 14 days by means of a QIAamp
DNA stool minikit (Qiagen, Valencia, CA), according to the manufactur-
er’s specifications, adopting a temperature of 95°C in step three to maxi-
mize bacterial cell lysis.
Profiling of fecal microbiota composition. The bacterial community
structure of fecal samples was determined by 16S rRNA gene profiling, as
previously described (18). In brief, a DNA fragment encompassing the
variable region V3 of the 16S rRNA gene was amplified from metag-
enomic DNA with the primers Probio_Uni (5=-CCTACGGGRSGCAGC
AG-3=) and Probio_Rev (5=-ATTACCGCGGCTGCT-3=) and was se-
quenced by means of Ion Torrent PGM sequencing technology (Life
Technologies, Carlsbad, CA). Specifically, emulsion PCR was performed
using the IonOneTouch 200 template kit version 2DL (Life Technologies,
Guilford, CT), according to the manufacturer’s instructions. Amplicon
library sequencing was performed on 316 Chips using the Ion sequencing
200 kit (Life Technologies). The sequencing runs were multiplexed, and
barcode sequences were used to discriminate the samples. Sequence reads
were then analyzed using the bioinformatic pipelineQuantitative Insights
Into Microbial Ecology (QIIME) version 1.7.0 (19) with the GreenGenes
database updated to version 13.5. Bacterial relative abundances in each
fecal sample were reported at the taxonomic levels of phylum, class, order,
family, and genus.
Quantification of fecal SCFAs. SCFAs were quantified in the fecal
samples from 25 out of 27 subjects who completed the intervention trial.
The remaining two subjects were excluded from the analysis due to insuf-
ficient fecal material availability. Fecal samples were extracted according
to Huda-Faujan et al. (20), with somemodifications. In detail, stool spec-
imens (100mg) were suspended in 2ml of 0.001%HCOOHand vortexed
for 1 min. The suspension was centrifuged at 1,000 g for 2 min at 4°C,
and the supernatant was recovered. The residue was extracted again, as
described above. The supernatants were combined, and the volume was
adjusted to 5 ml with a solution of 0.001%HCOOH in water. All extracts
were stored at20°C. Before ultraperformance liquid chromatography–
high-resolution-mass spectrometry (UPLC-HR-MS) analysis, samples
were diluted 1:100 in 0.001%HCOOH and centrifuged at 3,000 g for
1 min.
UPLC-HR-MS analysis was carried out on an Acquity UPLC separa-
tion module (Waters, Milford, MA, USA) coupled with an Exactive Or-
bitrap MS with an HESI-II probe for electrospray ionization (Thermo
Scientific, San Jose, CA, USA). The ion source and interface conditions
were as follows: spray voltage,3.0 kV, sheath gas flow rate, 35 arbitrary
units; auxiliary gas flow rate, 10 arbitrary units; temperature, 120°C; and
capillary temperature, 320°C. A 1.8-mHSS T3 column (150 by 2.1 mm;
Waters) was used for separation at a flow rate of 0.2 ml/min. The eluents
were 0.001% HCOOH in MilliQ-treated water (solvent A) and CH3OH:
CH3CN (1:1 [vol/vol], solvent B). A 5-l aliquot of the sample was sepa-
rated by the UPLC using the following elution gradient: 0% B for 4min, 0
to 15%B in 6min, 15 to 20%B in 5min, 20% for 13min, and then return
to initial conditions in 1 min. The column and samples were maintained
at 30 and 15°C, respectively. The UPLC eluate was analyzed in full-scan
MS in the range m/z 50 to 130. The resolution was set at 50 K, the auto-
matic gain control (AGC) target was 1E6, and themaximum ion injection
time was 100 ms. The ion with m/z 91.0038, corresponding to the formic
acid dimer [2M-H], was used as the lockmass. Themass tolerance was 2
ppm. The MS data were processed using Xcalibur software (Thermo Sci-
entific). Analytical-grade SCFAs were used as standards (Sigma-Aldrich,
Milan, Italy). Five-point external calibration curves were adopted to
quantify pyruvic, lactic, succinic, acetic, propionic, butyric, isobutyric,
valeric, and isovaleric acids in fecal samples. SCFA concentrations were
expressed in milligrams per kilogram of wet feces.
Statistics. Statistical analyses were performed using the R statistical
software (version 3.1.2). To measure valid outcomes, only participants
with 100% compliance with the treatments and the experiment protocol
were included in the analysis (per-protocol analysis). The numerical value
of 0 was given to any taxon that was absent in a specific sample to allow a
comparison. Because of the necessary crossover design for significant re-
sults, intention-to-treat analysis was not performed.Differences between
the effects on microbiota composition of probiotic and placebo treat-
ments were evaluated by analyzing the data with nonparametric
Wilcoxon-Mann-Whitney test with Benjamini-Hochberg correction
using paired data. In particular, we performed two separated statistical
analyses: in the first analysis, we compared data for each taxon before
versus after probiotic intake; in the second, data from the same sub-
jects were compared before versus after placebo. This analysis allowed
us to decide whether the population distributions were identical without
assuming them to display a normal distribution. A nonparametric test
derived from the Shapiro-Francia test was performed for the composite
hypothesis of normality. The P value was computed from the formula
given by Royston (21). Repeated-measures analysis of variance (ANOVA)
was used when the data were consistent with the assumption of a para-
metric test for normal distribution. Statistical significance was set at a P
value of0.05, andmean differences with 0.05 P 0.10 were accepted
as trends. To group subjects into enterotypes, the tutorial by the European
Molecular Biology Laboratory (EMBL) was used (http://enterotype.embl
.de/). With respect to differences in the absolute quantity of SCFAs, the
subjects were clustered using a Jensen-Shannon divergence (JSD) algo-
rithm based on the SCFA concentration. Moreover, the treatment re-
sponse was evaluated by performing the Wilcoxon-Mann-Whitney test
with Benjamini-Hochberg correction using the paired-data test.
Accession number(s). Sequence reads have been deposited in NCBI’s
Sequence Read Archive (ENA) under accession no. PRJEB11694.
RESULTS
Study compliance and questionnaire analyses. All participants
tolerated the capsules well, and no adverse events were reported.
Participants maintained their usual dietary habits during the
study, and no significant differences in the intake of potentially
prebiotic foods were observed. The only registered modifications
were related to slight seasonal differences in the availability of
fruits and vegetables (the study began in June and ended in Octo-
ber). Participants’ adherence to the study protocol was assessed
based on capsule counts and fecal sample collection, and compli-
ance was higher than 95%. In total, 38 participants were assessed
for eligibility, and 35 participants were randomly assigned; 27 par-
ticipants (77%) concluded the study, with 14 participants in the
randomization group A (6 females and 8 males) and 13 partici-
pants in group B (7 women and 6 men). The drop-out rate of
volunteers who began the first treatment was 20% (n  7), con-
sistent with the literature (6), and apparently justified by the strict
exclusion criteria and quite long duration of the study (four
months). No significant changes in stool consistency and evacua-
tion frequency were noted according to the analysis of data re-
ported in stool diaries (data not shown).
16S rRNA gene profiling revealed that the fecal microbiota
compositionwasmarkedly varied among theparticipants in the
PROBIOTA-Bb study. A total of 15,845,061 filtered high-quality
sequence reads were generated (average, 135,428 reads per sam-
ple), with amean standard deviation (SD) length of 179 4 bp.
Rarefaction curves indicated that most fecal microbiota diversity
had been covered (see Fig. S1A in the supplemental material). We
identified a total of 93 bacterial families and 190 bacterial genera,
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with a minimum number of 23 families and 38 genera and amax-
imum of 65 families and 125 genera per fecal sample. Only 17
generawere detected in all subjects at the 4 time points (8.9%of all
detected genera), and 47 generawere present in at least one sample
for all subjects (approximately 25% of all detected genera).
Subsequently, microbiota profiling data were stratified by en-
terotyping based on the relative abundances of the bacterial gen-
era (22). The microbiota compositions of all samples in this study
were clustered in two groups (Silhouette index [SI] 0.25; see Fig.
S2 in the supplementalmaterial) resembling theBacteroides-dom-
inant (Ba) and the Prevotella-dominant (Pr) enterotypes (22).
During the study, 8 of 27 subjects changed enterotypes; specifi-
cally, we observed 11 shifts from one enterotype to the other (ac-
counting for the 14.7% of all possible shifts), with 3 during the
probiotic intervention, 5 in the placebo treatment, and 3 in the
washout phase (Fig. S2B). Therefore, the treatments did not affect
the affiliation of subjects to enterotypes. Interestingly, bacterial
richness differed significantly between the two enterotype clusters:
the -diversity estimated by the Chao1 index was significantly
higher in the Ba group than in the Pr group of samples (see Fig. S3
in the supplemental material).
The analyses described below were conducted to identify the
effects induced by the probiotic intake on fecal microbial ecology
and were restricted to the participants who received the intended
interventions in accordance with the protocol (per-protocol anal-
ysis).
B. bifidum intake did not modify the - and -diversities of
the fecal microbiota. The effect of the probiotic intervention was
first investigated with respect to the modification induced by B.
bifidum intake on the richness and evenness of the operational
taxonomic units (OTUs) in each sample (-diversity) and the
intersample relationship of the bacterial compositions (	-diver-
sity). According to both parametric (repeated-measures ANOVA)
and nonparametric (Wilcoxon text) statistics, the intake of B. bi-
fidum did not significantly affect the intrasample biodiversity as
measured by the Chao1 and Shannon coefficients (predictors of
taxonomic richness and evenness; Fig. S1A and B in the supple-
mental material) or the intersample diversity determined by prin-
cipal-coordinate analysis (PCoA) based on weighted and un-
weighted UniFrac distances (measure of 	-diversity; Fig. S1C).
Probiotic intervention with B. bifidummodified the relative
abundance of dominant taxa in the fecal microbiota. The Wil-
coxon test with Benjamini-Hochberg correctionwas used to iden-
tify the bacterial taxa (from phylum to genus) that were signifi-
cantly affected by the probiotic or placebo treatments. This
nonparametric statistical analysis revealed that B. bifidum Bb in-
take had a greater impact than placebo on the relative abundance
of OTUs (see Table S1 in the supplementalmaterial). In detail, the
probiotic intervention induced the significant modification of 25
taxa, whereas only 13 taxa were different after placebo. More im-
portantly, only 1 OTU that changed during the placebo treatment
had a relative abundance above 1% (undefined members of the
Bacteroidales order, from 1.10 to 0.46%; P  0.036; Table S1),
whereas probiotic intake significantly modulated the abundance
of several dominant taxa of the fecal microbiota, including the
families Prevotellaceae (mean value of the relative abundances
from 14.18 to 11.97%; P  0.041), Rikenellaceae (from 3.99 to
5.92%; P 0.010), and Ruminococcaceae (from 12.21 to 15.27%;
P 0.039), and the genus Prevotella (from 14.16 to 11.96%; P
0.034) (Fig. 2; see also Table S1).
The statistical strength of the observed differences between the
effects induced by the two treatments is corroborated by the com-
parison of OTU relative abundances before treatments (i.e., for
samples collected at V1 and V3; Fig. 1). The Wilcoxon test re-
vealed that only three OTUs with relative abundances of less than
1%were significantly different between the placebo and probiotic
pretreatment phases (see Table S1 in the supplemental material).
We did not find a significant modulation of the genus Bifido-
bacterium by probiotic treatment, suggesting that the intake of a
billion B. bifidum cells was not enough to affect the relative abun-
dance of the entire genus. On the contrary, we found that the
relative abundance of the reads associated with the B. bifidum
species increased importantly upon probiotic consumption,
changing from a median below the detection limit to 0.005%. In
contrast, during placebo treatment, the relative abundance of B.
bifidum reads decreased from0.002% to below the detection limit.
Finally, we also observed that the impact of the probiotic inter-
vention on enterotypeswas greater on thePr group of samples (see
Table S2 in the supplemental material); this result, however, may
have been merely a reflection of the change in Prevotella levels.
Probiotic intervention modulated the fecal levels of bu-
tyrate.We quantified the concentration of SCFAs in fecal samples
by UPLC-HR-MS (see Table S3 in the supplemental material).
Statistical analyses (repeated-measures ANOVA and Wilcoxon
test) revealed that neither the probiotic nor placebo intervention
significantly affected the levels of SCFAs quantified in all fecal
samples (see Table S4 in the supplemental material).
Subsequently, we clustered subjects by PCoAbased on the con-
centrations of the most abundant fecal SCFAs, i.e., acetate, bu-
tyrate, and propionate. According to the highest Silhouette coef-
ficient of clustering prediction (SI  0.43), we separated the
samples in two groups (Fig. 3A), which do not correspond to
enterotype clusters. SCFA group H was characterized by higher
concentrations of acetate, butyrate, isovalerate, propionate, succi-
nate, and valerate than the second group (SCFA group L; Fig. 3B).
Furthermore, SCFA groupH exhibited significantly lower acetate/
butyrate and acetate/propionate ratios than SCFA group L (Fig.
3C). Subsequently, we investigated whether the intervention af-
fected fecal levels of taxa and SCFAs in the two groups.We did not
find significant modifications of taxon relative abundance upon
FIG 2 Relative abundance of dominant bacterial families in fecal samples
significantly modified by the probiotic treatment. Data are shown as Tukey
box plots. Statistically significant differences are according to the Wilcoxon-
Mann-Whitney test with Benjamini-Hochberg correction; *, P 0.05.
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probiotic or placebo treatment in the SCFA groups (see Table S5
in the supplemental material). On the contrary, we determined
that the probiotic (but, notably, not the placebo) treatment in-
duced a significant change in the fecal level of butyrate in both
SCFA groups (Fig. 3D; see also Table S3 in the supplemental ma-
terial). Specifically, the median of butyrate levels increased from
5.2 to 8.2 mg kg1 of wet feces in group L and dropped from 17.9
to 12.0 mg kg1 of wet feces in group H, erasing the significant
difference initially existing in the levels of this SCFA between the
groups (Fig. 3D). None of the other SCFAs were significantly af-
fected by the treatments (Table S3).
DISCUSSION
The PROBIOTA-Bb trial was undertaken to contribute to the
elucidation of the probiotic potential of strains of the species Bi-
fidobacterium bifidum, which is a specialized human commensal
possessing a large arsenal of host interaction properties (9). Spe-
cifically, we studied the impact of B. bifidum Bb on the intestinal
microbial ecology of healthy adults. Strain Bb was isolated from
the feces from a healthy adult woman and, according to in silico
analysis of its draft genome (our unpublished data), possesses the
genetic determinants known to support the B. bifidum-host inter-
action, including genes encoding sortase-dependent pili (12),mu-
cin-metabolizing enzymes (23), human-milk oligosaccharide hy-
drolases (24), BopA outer surface lipoprotein (10), and Tal
transaldolase (25). In this study, we used capsules containing ap-
proximately one billion viable Bb cells, which corresponds to the
minimal daily dosage recommended for probiotics by the Italian
Ministry of Health (26).
16S rRNA gene profiling revealed considerable variation of the
fecal microbiota composition of the volunteers enrolled in the
PROBIOTA-Bb trial, consistent with previous studies (27, 28).
These interindividual differences support the choice of the cross-
over design, in which individual participants serve as their own
controls, resulting in the reduction of interindividual variation.
To characterize the wide interindividual variability of the fecal
microbiota, we clustered subjects according to common features
FIG 3 Short-chain fatty acid (SCFA) cluster analysis. (A) Principal-coordinate analysis (PCoA; the first two principal components are shown); clustering was
based on the fecal concentrations of acetate, butyrate, and propionate using JSD distance and the Partitioning aroundMedoids (PAM) algorithm. (B) Tukey box
plots representing the proportion of main fecal SCFAs in groups H (displaying higher concentrations of SCFAs) and L (lower SCFA concentrations). (C) Tukey
box plots of the ratios between the threemain fecal SCFAs in groupsHandL. (D)Tukey box plots representing the effect of the probiotic andplacebo intervention
on butyrate levels in SCFA groups H and L. Asterisks are according to the Wilcoxon-Mann-Whitney test (with paired data, when possible) with Benjamini-
Hochberg correction to determine statistically significant differences between groups (B to D) and before and after the probiotic treatment (D). *, P 0.05; **,
P 0.01; ***, P 0.001; n.s., no significant difference.
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in the taxonomic composition. In light of the theory suggesting
that intestinal microbiota variation is generally stratified and not
continuous (22), we adopted the enterotype classification to clus-
ter the data collected during the PROBIOTA-Bb study, according
to the relative abundance of bacterial genera. The proposed ap-
proach for enterotyping is subject to limitations. In particular,
enterotyping reflects overconfidence in the assumption of discrete
enterotypes without consistent evidence to refute the simpler hy-
pothesis of continuous variation of the microbiota (29). The exis-
tence of discrete structures for gut microbiota has not been con-
vincingly demonstrated (30) and represents a crucial assumption
in applying an appropriate prediction model. Nonetheless, we
used the original tutorial to define enterotypes (http://enterotype
.embl.de/enterotypes.html) in the present study, because it has
been demonstrated to be useful to correlate the gut microbial
community structure with host biomarkers and diet (31, 32). In
our study, enterotyping clustered the microbiota taxonomic
structures of the fecal samples in two groups corresponding to the
most common enterotypes of healthy adult populations, namely,
the Bacteroides-dominant (Ba) and the Prevotella-dominant (Pr)
enterotypes (22, 33).
In our trial, the - and 	-diversities were not significantly af-
fected by probiotic intervention. In a recent intervention study
that was performed adopting the same trial design (6), the admin-
istration of capsules containing the probiotic strain Lactobacillus
paracasei DG did not modify the -diversity of participants’ fecal
samples, but, in contrast to the results of this study, induced a
significant change in the 	-diversity in terms of weighted UniFrac
distances. Kim et al. (34) did not observe significant alterations in
- and 	-diversities following the consumption of various probi-
otic products; however, a very limited number of subjects per
group (only three) were used in that study. Furthermore, no alter-
ations in - and 	-diversities were observed in the fecal microbi-
ota of 1- to 2-year-old children following the consumption of
probiotic milk containing Lactobacillus rhamnosus GG (LGG),
Lactobacillus acidophilus La-5, and Bifidobacterium animalis
subsp. lactisBb-12 (35). Other intervention trials investigating the
effect of probiotics on the intra- and interindividual biodiversities
of the gut microbiota in healthy subjects have not been reported.
Taken together, these data confirm the literature (although lim-
ited) suggesting that probiotic intake may be an insufficiently
weak perturbation to modify the - and 	-diversities of the intes-
tinal microbiota of healthy adults. This hypothesis is plausible in
light of the recognized stability throughout adulthood and the
reported resilience of the human intestinal microbiota to short-
term dietary changes (36).
This study revealed that the intervention with strain Bb af-
fected the relative abundances of several dominant taxa of the
intestinal microbiota; specifically, the families Ruminococcaceae
andRikenellaceae increased, whereas Prevotellaceae decreased. Re-
markably, Ruminococcaceae, Prevotellaceae, and Rikenellaceae (to-
gether with Lachnospiraceae and Bacteroidaceae) have been iden-
tified by metatranscriptomics as the predominant families of the
active microbiota (37).
Ruminococcaceae is a family of obligate anaerobes that include
bacteria (e.g., Faecalibacterium, Ruminiclostridium, and Rumino-
coccus spp.) that may degrade numerous polysaccharides in the
lower gastrointestinal tract, such as starch, cellulose, and xylan,
and produce SCFAs (38). The expansion of Ruminococcaceae in
centenarians has been reported, with a positive correlation with
high-fiber diets (39) and after intervention with resistant starch
(40). Furthermore, in the study by Martínez et al., Ruminococ-
caceae were more dominant in normoweight than obese individ-
uals and negatively correlated withmarkers of inflammation (41).
A lower abundance of this taxon was associated with exaggerated
Toll-like receptor 2 (TLR-2) responses and an increased risk of
developing IgE-associated eczema in infants (42). The relative
abundance of Ruminococcaceae was also lower in acute-on-
chronic liver failure patients (43); in the same study, a negative
correlation of Ruminococcaceae with tumor necrosis factor alpha
(TNF-) and interleukin 6 (IL-6) and endotoxemia was also ob-
served. Finally, two recent studies reported that Ruminococcaceae
are diminished in the guts of inflammatory bowel disease (IBD)
patients, particularly those with ileal Crohn’s disease (44, 45).
Therefore, a number of observations suggest that Ruminococ-
caceae are commonly associatedwith a healthy gutmicrobiota and
may exert a protective role on host health.
A couple of studies have also suggested a potential positive role
for Rikenellaceae, a Bacteroidales family significantly enhanced
by probiotic treatment with strain B. bifidum Bb. Specifically,
Rikenellaceae family members were depleted in patients who had
chronic HIV infection relative to HIV-uninfected controls (46)
and suppressed in IBD patients relative to healthy controls (45,
47). Conversely, one study reported a higher abundance of Rumi-
nococcaceae and Rikenellaceae and a decrease in the abundance of
Prevotellaceae in the terminal ileum microbiota of subjects with
ankylosing spondylitis (AS) compared with healthy controls (48).
In our study, the probiotic intervention reduced the relative
abundance of the familyPrevotellaceae and, particularly, the genus
Prevotella. The relative richness of Prevotella spp. and Prevotel-
laceae is frequently modulated following dietary interventions
(49, 50) and, in general, by lifestyle modifications (51), suggesting
that these microorganisms represent active and rapidly reacting
components of the human intestinal microbiota (37). Notably,
Prevotella spp. are the dominant colonizers of agrarian societies
and are associated with long-term diets rich in plant carbohy-
drates and fibers, whereas the abundance of Bacteroides spp. is
increased in individuals fromurbanized societies and is associated
with diets high in animal fat and proteins (33, 52). Although all
subjects enrolled in the present study lived in an urbanized Euro-
pean area (Lombardia region), Prevotellawas the dominant genus
in approximately 30% of study participants (8 of 27 subjects at
V1). This high prevalence of Prevotella in the population under
study may potentially be explained by the higher-than-average
fruit and vegetable (and thus fiber and starch) intake of Italian
subjects (53).
A few studies have suggested that the abundance of Prevotel-
laceae/Prevotella (Bacteroidetes phylum) is inversely associated
with the relative richness of Ruminococcaceae (Firmicutes phy-
lum). For instance, increased Ruminococcaceae have been pro-
posed to compensate for lower levels of Prevotellaceae in Parkin-
son’s disease patients (54). Conversely to Ruminococcaceae,
Prevotellaceae have been observed to be overrepresented in obese
people (55). Furthermore, although typically associated with
plant carbohydrate consumption, enriched abundance of Pre-
votella has also been linked to the high consumption of L-carni-
tine-containing foods, such as red meat (56).
Notably, several studies also suggested a potential role of Pre-
votellaceae as intestinal pathobionts. The family Prevotellaceae
was, in fact, demonstrated to elicit a strong inflammatory re-
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sponse in the guts of mice (57) and is overrepresented in patients
with ulcerative colitis (58). An increase in Prevotella spp. was also
reported in the intestinal lumen microbiota of colorectal cancer
patients (59) and in children diagnosed with irritable bowel syn-
drome (60). Finally, the species Prevotella copri was identified as
strongly correlated with disease in new-onset untreated rheuma-
toid arthritis patients (61). However, increased abundance of P.
copri has also been associated with dietary fiber-induced improve-
ment in glucose and insulin responses (62). In addition, low Pre-
votellaceae levels have been reported in patients with type 1 diabe-
tes (63) and children with autism (64). However, a subsequent
study involving a larger population of autistic children reported
the opposite result (i.e., a significant increase in Prevotella spp.
[65]). In conclusion, the scientific literature is far from a final and
unambiguous understanding of the role of a specific taxon in host
health; plausibly, the same bacterial taxa of the gut microbiota
may exert opposite effects on the host (health preserving versus
health threatening), depending on physiological background.
This variability is particularly true for Prevotella spp., which ap-
pear to be critical bacteria for healthy microbiota that have been
linked to plant-rich diets but also to chronic inflammatory condi-
tions (66). In addition, genera such as Prevotella include numer-
ous species that possess wide genetic diversity, which may at least
partially explain the observed differences in interactions between
Prevotella and its host (66).
Modification of the intestinalmicrobiota structuremay poten-
tially lead to alterations of the gut levels of SCFAs, which are mi-
crobial metabolic products exerting a number of effects on host
physiology (67). Diet (probiotics included) may modify the level
of SCFAs in the intestinal lumen by affecting their uptake/utiliza-
tion by host and intestinal microbes or by changing the relative
abundance of specific butyrate-producing bacteria. In our study,
we observed themodification ofClostridiales bacteria of the family
Ruminococcaceae, which are among the primary producers of
SCFAs and, in particular, butyrate in the human large intestine.
We therefore quantified the concentrations of SCFAs in fecal sam-
ples by UPLC-HR-MS. We observed that subjects could be clus-
tered into groups, H and L, according to the levels of the three
most abundant SCFAs. GroupHwas characterized by higher con-
centrations of several SCFAs, including butyrate, than those in
group L. Notably, we observed that the probiotic treatment in-
duced a significant change in butyrate levels, which decreased in
group H and increased in L. Notably, this modification was not
observedwith placebo treatment. A similar effect on fecal butyrate
levels was also observed during an intervention study with the
probiotic strain Lactobacillus paracasei DG (6). In light of litera-
ture suggesting that excessive intestinal butyrate may be detri-
mental in certain physiological conditions, such as irritable bowel
syndrome (IBS) or metabolic syndrome (68–71), although con-
sidered improbable by some researchers (72), we recently postu-
lated the potential existence of an optimal butyrate concentration
range in the human intestine (6, 73). In this context, the hypoth-
esis can be made that probiotics might be used to decrease high
butyrate concentrations or increase low butyrate concentrations
to maintain butyrate homeostasis in healthy people, potentially
preventing disorders associated with altered butyrate levels (73).
In conclusion, in our study, the probiotic treatment modified
the relative abundances of bacterial taxa that have often been as-
sociated with health conditions; in addition, the probiotic treat-
ment modulated the fecal levels of butyrate, a microbial metabo-
lite exertingmultiple effects on humanhealth. Therefore, the daily
consumption of B. bifidum Bb cells may affect human health;
however, as for most dietary interventions, the current state of
knowledge does not allow us to better define the significance of
any taxonomic or metabolite changes of the intestinal microbial
ecosystem on the host health.
In a wider perspective, the PROBIOTA-Bb trial contributes to
the field of research on probiotics in healthy populations, which is
currently attracting significant attention in the context of probi-
otic health claim assessment by the EFSA. In particular, our study
demonstrates that a single daily administration of one bacterial
strain approximately at theminimal recommended dose (1 billion
CFU [26]) can modify the human intestinal microbial ecology of
healthy (not diseased) adults in a significant fashion. These find-
ings emphasize the need to reassess the notion that probiotics do
not influence the complex and stable intestinal microbial ecosys-
tem of a healthy individual and the importance of a proper inter-
vention setting coupled with the use of adequate analytical and
bioinformatic tools.
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